Practice Management News

Conatus Pharmaceuticals Inc. announced results from its phase 2 clinical trial of emricasan, which showed reduced MELD score, caspase-cleaved cytokeratin 18 serum and other biomarkers in patients with liver cirrhosis treated with emricasan vs. placebo.

After an 18-month investigation into the pricing of Harvoni, members of the U.S. Senate Committee on Finance found that Gilead Sciences chose its price with a goal of maximizing revenue as opposed to treating as many patients with hepatitis C virus infection as possible.

The FDA has determined Fujifilm Medical Systems’ revised, validated manual reprocessing instructions for its ED-530XT duodenoscope meet the agency’s expectations and should be implemented as soon as possible, according to an FDA press release.

ORLANDO, Fla. — Paul G. Richardson, MD, summarizes updated results of a trial presented at the ASH Annual Meeting and Exposition that evaluated defibrotide for the treatment of patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome associated with multi-organ failure after chemotherapy.

Numerous developments were made in the field of Hepatology this year, as well as new, groundbreaking data on nonalcoholic fatty liver disease, cirrhosis and liver transplantation, presented at the biggest Hepatology conferences. Using web analytics, social media and expert opinion, Healio.com/Hepatology has compiled a list of the most read research and news in hepatology presented during the past year.

ACP and the AMA are calling for changes to the current meaningful use program to better align with the needs of physicians and patients, according to press releases issued by the organizations.

AGA has released a statement in support of the American Board of Internal Medicine’s decision to extend its suspension of practice improvement, patient safety and patient voice requirements for its Maintenance of Certification program through Dec. 2018.

The ABIM Board of Directors voted to extend the board's practice assessment decision through 2018, according to a press release.

Recent data show that gastrointestinal, liver and pancreatic diseases continue to be source of significant burden and cost in the U.S.

SAN FRANCISCO — According to data presented at The Liver Meeting 2015, people who abstained from drinking alcohol for at least 1 month had a reduced risk for nonalcoholic fatty liver disease and improved insulin resistance.